Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

In a historic first, Saudi Arabia has approved Leqembi (lecanemab)—a breakthrough drug that targets early-stage ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

LEQEMBI is the only FDA- approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. TOKYO and CAMBRIDGE, Mass., Jan ...